Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic drug. It is marketed as Amaryl by Sanofi-Aventis. Glimepiride is the first third-generation sulfonylurea, and is very potent.
It is sometimes classified as third-generation,[1] and sometimes classified as second-generation.[2]
Indications
Type 2 diabetes (NIDDM).
Adverse effects
Main article: Sulfonylurea
GI disturbance, rarely thrombopenia , leucopenia, haemolytic anaemia, occasionally allergic. In the initial weeks of treatment, the risk of hypoglycemia may be increased.
Contraindications
-Hypersensitivity to glimepiride or other sulfonylureas.
-Pregnancy
Interactions
With NSAIDs like Salicylates, Sulphoamides, Chlorampenicol, coumarin and probencid may potentiate the hypoglycemic action of glimepiride. Thiazides, other diuretic, phothiazides, thyroid products, oral contraceptives, phenytoin tend to produce hyperglycemia.
No comments:
Post a Comment